← back to search

Adam Langenbucher

Allen Institute ·
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Cancer research, Biology, Pancreatic cancer, Genetics, Cancer, and Crizotinib.
h-index
citations
1,533
works
11
NIH funding
primary concept
email

Recent publications

Leukemia circulation kinetics revealed through blood exchange method
Communications Biology 2024cited by 2position: middledoi
Abstract B060: Unveiling resistance mechanisms to CAR T-cell therapy in pancreatic cancer through in vivo CRISPR/Cas9 knockout screening
Cancer Research 2024cited by 0position: middledoi
Abstract B039: Elucidating the tumor-driven mechanisms of resistance to immunotherapies in pancreatic cancer through in vivo CRISPR/Cas9 knockout screening
Cancer Immunology Research 2024cited by 0position: middledoi
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
Clinical Cancer Research 2021cited by 137position: middledoi
NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer
Molecular Cell 2021cited by 69position: middledoi
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Clinical Cancer Research 2020cited by 193position: middledoi
Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of <i>BRCA2</i> mutation carriers
Science Advances 2020cited by 44position: middledoi
A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells
Genome biology 2020cited by 31position: middledoi
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
Cell 2019cited by 531position: middledoi
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features
Science 2019cited by 324position: middledoi
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Nature Medicine 2018cited by 202position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael S. Lawrence · Harvard University3 papers (2019–2020)Michael T. Hemann · Massachusetts Institute of Technology3 papers (2024–2024)Charles A. Whittaker · Massachusetts Institute of Technology2 papers (2024–2024)Cyril H. Benes · Virginia Commonwealth University2 papers (2019–2020)Daniel R. Goulet · Massachusetts Institute of Technology2 papers (2024–2024)P Leclerc · Massachusetts Institute of Technology2 papers (2024–2024)Riley D. Hellinger · Massachusetts Institute of Technology2 papers (2024–2024)Eugene E. Kwan · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2019–2019)Ibiayi Dagogo‐Jack · Center for Cancer Research1 papers (2020–2020) · 1 papers (2019–2019)Rémi Buisson · Center for Cancer Research1 papers (2019–2019)Satoshi Yoda · Harvard University1 papers (2020–2020) · 1 papers (2020–2020)Mihriban Karaayvaz · Center for Cancer Research1 papers (2020–2020)Christopher G. Azzoli · Rhode Island Hospital1 papers (2020–2020)Subba R. Digumarthy · Harvard University1 papers (2020–2020)Leif W. Ellisen · Harvard University1 papers (2020–2020)Srinivas Vinod Saladi · Center for Cancer Research1 papers (2020–2020)Jochen K. Lennerz · Addgene1 papers (2020–2020)Andrew Do · Global Cancer Institute1 papers (2020–2020)